Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Variants & evidence
296 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| IKZF1 Deletion4 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID7403The authors showed that in addition to the commonly observed exon 4-7 deletions and whole-gene deletions, rare IKZF1 deletions (DEL 2-7, DEL 2-8 and others) were also associated with inferior prognos… (full text at CIViC) PMID 26202931 · Boer et al., 2016 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID7541This study reports on a cohort of NCI high-risk, Ph-negative pediatric patients with B-ALL. Twenty eight out of 94 patients (~30%) were found to harbor IKZF1 deletions, which were associated with male… (full text at CIViC) PMID 29507076 · Tran et al., 2018 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID9238An analysis of clinical and molecular data (n=239) from acute lymphoblastic leukemia (B-ALL) revealed that deletion of the tumor suppressor IKZF1 results in poor prognosis of B-ALL in Hispanic/Latino … (full text at CIViC) PMID 33531655 · Raca et al., 2021 · Open in CIViC | civic |
| Cytarabine + Daunorubicin + Fludarabine + Imatinib + MethotrexateCombination | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID7366This prospective study reports on the prognosis of patients with B-ALL and an IKZF1 deletion and the impact of intensification of treatment in this subgroup. In 50 patients from the MS2003 cohort, th… (full text at CIViC) PMID 30044693 · Yeoh et al., 2018 · Open in CIViC | civic |
| CDKN2A Deletion + CDKN2B Deletion + ERG Deletion + IKZF1 Deletion + CRLF2 Fusion + PAX5 DeletionPAX5CDKN2BERGIKZF1CRLF2CDKN2A1 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 5 | submitted | EID778683 of 991 cases of pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) were found to have IKZF1 deletion, previously reported as an independent factor associated with a poor prognosis.… (full text at CIViC) PMID 29498923 · Stanulla et al., 2018 · Open in CIViC | civic |
| IL7R S185C1 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 4 | submitted | EID6226The manuscript shows that somatic gain-of-function mutations in IL7R occur in the cases of pediatric B-lymphoblastic leukemias characterized by aberrant expression of cytokine receptor-like factor 2 (… (full text at CIViC) PMID 21536738 · Shochat et al., 2011 · Open in CIViC | civic |
| JAK1 S646F1 | ||||||||
| Ruxolitinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID7957A patient derived Ph-like B-ALL Xenograft (V) harboring the JAK1 S646F mutation was treated with ruxolitinib. Compared to vehicle, the ruxolitinib treated Xenograft had lower peripheral and splenic b… (full text at CIViC) PMID 22955920 · Maude et al., 2012 · Open in CIViC | civic |
| JAK2 F694L1 | ||||||||
| Ruxolitinib | B Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7021A 17-year-old Native American female with B-ALL had persistent MRD at the end of induction. In addition to a complex karyotype, sequencing revealed a novel F694L mutation in JAK2, a p.Cys119_Ile121del… (full text at CIViC) PMID 27860260 · Mayfield et al., 2017 · Open in CIViC | civic |
| FGFR1 e15::e111 | ||||||||
| (oncogenic) | B Acute Lymphoblastic LeukemiaALIAS | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID1172528 yo with acute B-lymphoblastic leukemia. RNA seq showed KIF5B::FGFR1 fusion. Fusion was reported to be in-frame. The FGFR1 fusion and its protein expression were validated by Sanger sequencing and W… (full text at CIViC) PMID 38023217 · Zhang et al., 2023 · Open in CIViC | civic |
| KMT2A Rearrangement1 | ||||||||
| (diagnostic) | B Acute Lymphoblastic LeukemiaALIAS | Diagnostic | A | Supports Positive | 5 | submitted | EID8601B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged, is a well- defined subgroup in the current WHO classification of hematologic malignancies. PMID 27069254 · Arber et al., 2016 · Open in CIViC | civic |
| KMT2A Fusion3 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12473In this study, the authors used long-distance inverse PCR and sequencing to comprehensively analyze KMT2A (MLL) gene rearrangements in 2,345 acute leukemia patients, including those with B-lymphoblast… (full text at CIViC) PMID 28701730 · Meyer et al., 2018 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12474In this publication, the authors conducted a comprehensive genomic analysis of 2,754 pediatric acute lymphoblastic leukemia (ALL) cases using integrated whole genome, exome, and transcriptome sequenci… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC | civic |
| 〃 | ||||||||
| ABL1 Fusion2 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9080This retrospective study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR … (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID9153This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions who were treated with a combination of tyrosine kinase … (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| BCL9 Fusion1 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12177This study was an international, multi-center retrospective analysis of 107 patients with MEF2D rearrangements, with information collected from 14 different regional study groups. The aim was to asses… (full text at CIViC) PMID 36309560 · Ohki et al., 2023 · Open in CIViC | civic |
| CSF1R Fusion2 | ||||||||
| Imatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID9360This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| Panobinostat | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID9359In this study, 560 cases of B-ALL were analyzed by RNAseq, 22 (3.9%) of which (3.9%) demonstrated rearrangements of MEF2D at chromosome 1q21–22, encoding myocyte enhancer factor 2D, representing 15 of… (full text at CIViC) PMID 27824051 · Gu et al., 2016 · Open in CIViC | civic |
| MEF2D MEF2D Rearrangement1 | ||||||||
| (prognostic) | B Acute Lymphoblastic LeukemiaALIAS | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID8624MEF2D encodes myocyte enhancer factor 2D and is mapped to chromosome 1q21–22. It is expressed throughout B-cell differentiation and inactivation of Mef2c/d results in an arrest in B-lymphoid maturatio… (full text at CIViC) PMID 27824051 · Gu et al., 2016 · Open in CIViC | civic |
| TYK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID12810In this 2014 genomic profiling study of 1,725 patients with precursor B-cell acute lymphoblastic leukemia (B-ALL), the authors define the high-risk "Philadelphia chromosome-like" (Ph-like or BCR::ABL1… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| NT5C2 R238W1 | ||||||||
| Mercaptopurine + ThioguanineSubstitutes | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Resistance | 2 | submitted | EID8077Lentiviral-mediated overexpression of NT5C2 R238W (a relapse specific variant) in Reh cells resulted in resistance against thiopurines (mercaptopurine and thioguanine) compared to NT5C2 wildtype overe… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC | civic |
| ABL1 Fusion2 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9079This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq perf… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 1 | submitted | EID11616B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 1 patient (12.1 years old) with a… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| ABL1 Fusion10 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Better Outcome | 3 | accepted | EID9148A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-… (full text at CIViC) PMID 33357483 · den Boer et al., 2021 · Open in CIViC | civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9074Transcriptome and whole genome sequencing were performed on 15 cases of B-lymphoblastic leukemia/lymphoma (B-ALL) that were previously shown to have a BCR-ABL1-like (Ph-like) expression signature. Two… (full text at CIViC) PMID 22897847 · Roberts et al., 2012 · Open in CIViC | civic |
| Dasatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | ||||||
| JAK2 Fusion2 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID7997To identify potentially druggable kinase fusions, this study of 278 B-ALL patients (all BCR-ABL1 negative), 34 (12.2%) harbored an IKZF1 deletion as determined by MLPA. Sufficient RNA from 16/34 of th… (full text at CIViC) PMID 26404892 · Yano et al., 2015 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID8104In this study involving 373 high risk pediatric B-ALL cases with no recurrent fusions, 29 were kinase-fusion positive as determined by mRNA-seq or mRT-PCR and validated by RT-PCR and Sanger. One case,… (full text at CIViC) PMID 27176795 · Imamura et al., 2016 · Open in CIViC | civic |
| CRLF2 Fusion4 | ||||||||
| (prognostic) | Adult B Acute Lymphoblastic LeukemiaALIAS | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID7211CRLF2 overexpression was examined in 90 adult B-ALL patients with demographic data that lacked characteristic rearrangements and identified overexpression in 15/90 (16.67%). Disease-free survival was … (full text at CIViC) PMID 20018760 · Yoda et al., 2010 · Open in CIViC | civic |
| (diagnostic) | Adult B Acute Lymphoblastic LeukemiaALIAS | Diagnostic | B | Supports Positive | 4 | submitted | EID7213CRLF2 overexpression was performed by Q-PCR, IHC, and gene-expression profiling of 254 adult B-ALL samples. CRLF2 overexpression was identified in 15/120 (12.5%) or adult B-ALL cases that lacked chara… (full text at CIViC) PMID 20018760 · Yoda et al., 2010 · Open in CIViC | civic |
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | |||||||
| ABL2 Fusion2 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID9721In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12872In a study using whole genome, exome and transcriptome sequencing of 2,754 childhood ALL patients, one patient with Ph-like B-ALL had PAG1::ABL2 reported. Patient ID was SJBALL020980. RNAseq, WES, WGS… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC | civic |
| AUTS2 Fusion1 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID12838The PAX5::AUTS2 represents a rare primary oncogenic driver in B-lymphoblastic Leukemia/lymphoma (B-ALL). An international cohort of 50 patients—including 16 previously reported cases—was assembled, w… (full text at CIViC) PMID 39702796 · Caye-Eude et al., 2025 · Open in CIViC | civic |
| JAK2 Fusion6 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | B | Supports Positive | 3 | accepted | EID7699In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7700In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on CRLF2 n… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports | ||||
| PAX5 P80R2 | ||||||||
| (diagnostic) | B Acute Lymphoblastic Leukemia with PAX5 P80R MutationALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID11519RNA-seq transcriptome analysis in a discovery cohort of 170 B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases negative for the common classifying cytogenetic aberrations identified severa… (full text at CIViC) PMID 30510083 · Passet et al., 2019 · Open in CIViC | civic |
| 〃 | B Acute Lymphoblastic Leukemia with PAX5 P80R MutationALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID7290In a large-scale international study RNA sequencing was performed to delineate the transcriptome landscape of 1,223 B-cell ALL cases. Twenty two cases were found to have P80R misense mutation in the D… (full text at CIViC) PMID 30487223 · Li et al., 2018 · Open in CIViC | civic |
Data updated 4 minutes agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS |
| Diagnostic |
| B |
| Supports Positive |
| 4 |
| accepted |
EID12475In this publication, the diagnostic significance of KMT2A rearrangements in B-lymphoblastic leukemia/lymphoma (B-ALL) is explored. The study reveals that KMT2A fusions are not restricted to lymphoid l… (full text at CIViC) PMID 38686611 · Aypar et al., 2024 · Open in CIViC |
| civic |
| Supports Sensitivity Response |
| 3 |
| submitted |
EID13328Of 40 patients with BCR::ABL1-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL), one 16-year-old male was found to have a NUP214::ABL1 fusion identified by genomic profiling (RT-PCR, next-gen… (full text at CIViC) PMID 25049327 · Roberts et al., 2014 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID13327A 26-year-old female with Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL) had a NUP214::ABL1 fusion detected by a next-generation sequencing panel experienced persis… (full text at CIViC) PMID 31014138 · Aldoss et al., 2019 · Open in CIViC | civic |
| Dasatinib + ImatinibSubstitutes | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12385Functional activity and treatment response were evaluated for several fusions identified in patients with gene expression profiles showing BCR::ABL1-like B-ALL. Phosphoflow on leukemic samples from 2 … (full text at CIViC) PMID 22897847 · Roberts et al., 2012 · Open in CIViC | civic |
| Dasatinib + NilotinibSequential | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID13329A 21-year-old patient with refractory B-cell acute lymphoblastic leukemia (B-ALL) had a NUP214::ABL1 fusion identified by clinical next-generation sequencing failed multiple prior treatment regimens, … (full text at CIViC) PMID 37933765 · Shumock et al., 2023 · Open in CIViC | civic |
| Dasatinib + Dexamethasone + VincristineCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7208A 15-year-old girl with B-cell precursor ALL was placed into the very high risk group after showing corticoid resistance on treatment day 8, and induction failure on day 35 (MRD >0.01). The patient re… (full text at CIViC) PMID 26681761 · Duployez et al., 2016 · Open in CIViC | civic |
| Dasatinib + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13330In a cohort of six patients with NUP214::ABL1-positive Ph-like B-ALL, detected by multiplex molecular assays for fusion transcript identification, including RNA sequencing, treatment with ABL-directed… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| Imatinib Mesylate | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID12218A 15-year-old male was diagnosed with B-cell ALL with a normal male karyotype by microarray (no aberrations >5Mb), normal FISH (including BCR::ABL1 and ABL1 breakapart) and aberrant phenotype B-lympho… (full text at CIViC) PMID 36172171 · Stukaite-Ruibiene et al., 2022 · Open in CIViC | civic |
| Dasatinib + Imatinib + Nilotinib + PonatinibSubstitutes | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 2 | accepted | EID9150A 22-year-old male with B-cell acute lymphoblastic leukemia was treated with induction therapy. FISH using a BCR-ABL1 probe demonstrated 50-80 extrachromosomal copies of ABL1; FISH using probes to the… (full text at CIViC) PMID 23175662 · Eyre et al., 2012 · Open in CIViC | civic |
| Prognostic |
| B |
| Supports Poor Outcome |
| 3 |
| submitted |
EID6231CRLF2 overexpression due to P2RY8-CRLF2 fusion or IGH translocation was found in 14% of high risk pediatric B-ALL cases (in the cohort of 209 high-risk patients). 62% of the cases had IGH translocatio… (full text at CIViC) PMID 20139093 · Harvey et al., 2010 · Open in CIViC |
| civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 1 | accepted | EID11622In this 2014 study by Roberts et al., a genomic analysis of 1725 patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) was conducted to define the genetic landscape of the Philadelphia c… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| 3 |
| submitted |
EID7701This study evaluated the prevalence and outcome of Ph-like ALL subtype in patients wiiht standard-risk (SR) disease. A cohort of 1023 SR cases from the Children's Oncology Group AALL0331 clinical tria… (full text at CIViC) PMID 29997224 · Roberts et al., 2018 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | submitted | EID8098In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 798 B-ALL patients of whi… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID8105In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 373 high risk pediatric B… (full text at CIViC) PMID 27176795 · Imamura et al., 2016 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 1 | submitted | EID11623B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 1 patient (5.3 years old) with a P… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |